$MTEM
Molecular Templates, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016027814 Filed on November 07, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $0.00 $3.680M
YoY Change -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.950M $2.370M
YoY Change -13.33% -1.66%
% of Gross Profit
Research & Development $3.010M $8.081M
YoY Change -73.53% -9.26%
% of Gross Profit
Depreciation & Amortization $20.00K $250.0K
YoY Change -92.0% -16.67%
% of Gross Profit
Operating Expenses $4.960M $10.45M
YoY Change -63.58% 17.37%
Operating Profit
YoY Change
Interest Expense $40.00K $30.00K
YoY Change 33.33% 0.0%
% of Operating Profit
Other Income/Expense, Net $1.250M $320.0K
YoY Change -92.83% -194.12%
Pretax Income -$3.680M -$6.430M
YoY Change -105.28% -19.09%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.682M -$6.431M
YoY Change -105.28% -16.97%
Net Earnings / Revenue -174.76%
Basic Earnings Per Share -$0.05 -$0.09
Diluted Earnings Per Share -$0.05 -$0.09
COMMON SHARES
Basic Shares Outstanding 71.56M 71.38M
Diluted Shares Outstanding 71.38M

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.700M $56.40M
YoY Change -96.51% -16.69%
Cash & Equivalents $1.716M $13.70M
Short-Term Investments $42.70M
Other Short-Term Assets $7.000K $1.800M
YoY Change -99.73% -5.26%
Inventory
Prepaid Expenses $120.0K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $1.843M $62.20M
YoY Change -96.53% -16.06%
LONG-TERM ASSETS
Property, Plant & Equipment $334.0K $400.0K
YoY Change 0.3% -33.33%
Goodwill $0.00
YoY Change
Intangibles $921.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.300M
YoY Change -100.0% 8.33%
Total Long-Term Assets $22.44M $1.800M
YoY Change 4396.99% -30.77%
TOTAL ASSETS
Total Short-Term Assets $1.843M $62.20M
Total Long-Term Assets $22.44M $1.800M
Total Assets $24.28M $64.00M
YoY Change -54.75% -16.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $822.0K $400.0K
YoY Change 13.38% -88.24%
Accrued Expenses $888.0K $9.100M
YoY Change -72.84% 33.82%
Deferred Revenue
YoY Change
Short-Term Debt $7.300M $0.00
YoY Change
Long-Term Debt Due $2.400M
YoY Change
Total Short-Term Liabilities $13.77M $24.30M
YoY Change 27.12% -2.8%
LONG-TERM LIABILITIES
Long-Term Debt $3.165M $0.00
YoY Change
Other Long-Term Liabilities $53.00K $70.60M
YoY Change -97.35% -2.89%
Total Long-Term Liabilities $3.218M $70.60M
YoY Change 60.9% -2.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.77M $24.30M
Total Long-Term Liabilities $3.218M $70.60M
Total Liabilities $17.03M $94.90M
YoY Change 32.82% -2.87%
SHAREHOLDERS EQUITY
Retained Earnings -$40.37M
YoY Change -87.74%
Common Stock $568.0K
YoY Change -99.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$39.81M -$30.90M
YoY Change
Total Liabilities & Shareholders Equity $3.098M $64.00M
YoY Change -94.23% -16.56%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$3.682M -$6.431M
YoY Change -105.28% -16.97%
Depreciation, Depletion And Amortization $20.00K $250.0K
YoY Change -92.0% -16.67%
Cash From Operating Activities -$830.0K -$10.72M
YoY Change -89.04% -3.94%
INVESTING ACTIVITIES
Capital Expenditures -$70.00K -$50.00K
YoY Change 25.0%
Acquisitions
YoY Change
Other Investing Activities -$220.0K $13.59M
YoY Change -106.43% 20.91%
Cash From Investing Activities -$290.0K $13.53M
YoY Change -108.48% 20.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.210M 340.0K
YoY Change 3933.33% -92.83%
NET CHANGE
Cash From Operating Activities -830.0K -10.72M
Cash From Investing Activities -290.0K 13.53M
Cash From Financing Activities 1.210M 340.0K
Net Change In Cash 90.00K 3.150M
YoY Change -102.18% -34.1%
FREE CASH FLOW
Cash From Operating Activities -$830.0K -$10.72M
Capital Expenditures -$70.00K -$50.00K
Free Cash Flow -$760.0K -$10.67M
YoY Change -89.96% -4.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Assets Current
AssetsCurrent
53170000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9589000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71560294
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
39091000
CY2015Q4 thld Collaboration Receivable
CollaborationReceivable
1891000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2599000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
131000
CY2015Q4 us-gaap Liabilities
Liabilities
12823000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
71000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71462059
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
370236000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-329440000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
40846000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53669000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71462059
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
10453000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5857000
CY2015Q3 us-gaap Contracts Revenue
ContractsRevenue
3680000
us-gaap Contracts Revenue
ContractsRevenue
0
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8081000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1124000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
378000
CY2015Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
us-gaap Net Income Loss
NetIncomeLoss
-20412000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
62000
us-gaap Share Based Compensation
ShareBasedCompensation
2437000
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1124000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1743000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
753000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-14000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-1491000
thld Increase Decrease In Receivables From Collaboration Partners
IncreaseDecreaseInReceivablesFromCollaborationPartners
-3216000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1638000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-100000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
22000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
90000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11041000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20478000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-30427000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-6431000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
109000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
15146000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
46622000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
71000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-26000
thld Increase Decrease In Accrued Clinical And Development Liabilities
IncreaseDecreaseInAccruedClinicalAndDevelopmentLiabilities
-4926000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2157000
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
68000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71536000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
12955000
CY2016Q3 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
5
CY2015Q4 us-gaap Severance Costs1
SeveranceCosts1
2500000
CY2016Q3 us-gaap Severance Costs1
SeveranceCosts1
700000
CY2015Q4 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000
CY2016Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71382000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71512000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
69833000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
792000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1476000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2437000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4792000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9032136
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2945000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6187
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
843098
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11127851
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11048510
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7854716
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.53
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.34
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.03
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.04
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.54
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y7M2D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M6D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
378524
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
370312
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
61500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
us-gaap Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions
0
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
27891000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
48510000
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
12953000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39112000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
22000
thld Weighted Average Maturity For Available For Sale Securities
WeightedAverageMaturityForAvailableForSaleSecurities
P2Y4M24D
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
196000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
260000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
456000
CY2015Q4 us-gaap Restructuring And Related Cost Expected Number Of Positions Eliminated
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
40

Files In Submission

Name View Source Status
0001564590-16-027814-index-headers.html Edgar Link pending
0001564590-16-027814-index.html Edgar Link pending
0001564590-16-027814.txt Edgar Link pending
0001564590-16-027814-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
thld-10q_20160930.htm Edgar Link pending
thld-20160930.xml Edgar Link completed
thld-20160930.xsd Edgar Link pending
thld-20160930_cal.xml Edgar Link unprocessable
thld-20160930_def.xml Edgar Link unprocessable
thld-20160930_lab.xml Edgar Link unprocessable
thld-20160930_pre.xml Edgar Link unprocessable
thld-ex311_9.htm Edgar Link pending
thld-ex312_8.htm Edgar Link pending
thld-ex321_7.htm Edgar Link pending
thld-ex322_6.htm Edgar Link pending
thld-ex32_171.htm Edgar Link pending